Valneva Usa, Inc.

Valneva USA, Inc., doing business as Intercell USA Inc., is a specialty vaccine manufacturer and foreign-owned subsidiary of French-based Valneva SE that operates exclusively as a prime contractor supplying Japanese encephalitis vaccine (IXIARO) and other immunological products to federal agencies on a firm fixed-price basis. The company competes full-and-open with no set-aside designation across the vast majority of its federal portfolio, though two small recent purchase orders (totaling $347,272) carry Total Small Business set-aside designations.

Valneva USA's federal footprint is heavily concentrated in a single customer and product line. The Defense Logistics Agency Troop Support Medical accounts for 51 of 157 total awards and $730.5 million of the $870.4 million combined potential value across the portfolio — 84% of dollars. The company's three primary indefinite delivery vehicles with DLA Troop Support Medical are valued at $49.3 million (single-award IDC, awarded January 29, 2025, completion January 28, 2026), $48.0 million (single-award IDC, awarded September 22, 2023, completion September 21, 2024), and a third vehicle referenced in award narratives at approximately $165.9 million, collectively enabling delivery orders for IXIARO vaccine to support the Department of Defense medical countermeasures program. Recent representative DLA work includes an $8.25 million delivery order (October 23, 2025) for IXIARO, a $5.15 million delivery order (January 22, 2026) for Japanese encephalitis vaccine, and a $4.41 million delivery order (January 7, 2026) for the same vaccine. The Department of Health and Human Services Office of the Assistant Secretary for Administration represents the second customer by volume (63 awards) but only $3.8 million in combined potential value, reflecting a pattern of small, frequent orders for IXIARO vaccine stock against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The Department of Veterans Affairs Veterans Integrated Service Network 12 represents 25 awards valued at $8.9 million, issued under the same GSA Schedule vehicle. The Department of Justice Federal Bureau of Investigation maintains a Blanket Purchase Agreement with Valneva USA for a range of vaccines including hepatitis A and B, MMR, tetanus, diphtheria, meningitis, rabies, polio, typhoid, and yellow fever, with 10 awards totaling $500 thousand. Concentration is extreme: the top two customers (DLA and HHS ASA) account for 114 of 157 awards and approximately $734.3 million of $870.4 million in potential value.

Valneva USA holds a Department of Veterans Affairs Federal Supply Schedule contract for Pharmaceuticals and Drugs (ceiling $4,026,865, expiring September 28, 2030) awarded September 29, 2025. The company's primary contracting vehicles are DLA Troop Support Medical indefinite delivery contracts, each yielding multiple firm fixed-price delivery orders throughout their performance periods. The company is the sole supplier on its major DLA IDCs, reflecting single-award vehicle status. Recent activity has been consistent but flat — 10 awards in 2024 and 10 awards in 2025 — with 157 total awards spanning back to 2007 and $330.8 million in obligated dollars representing 38% of potential value. Only three awards face ultimate completion within the next twenty-four months, carrying $841 thousand in combined potential value, presenting minimal near-term recompete exposure.

The firm's capability footprint is narrow and specialized. The vendor portfolio is dominated by Pharmaceutical Preparation Manufacturing NAICS (88 awards) and Biological Product Manufacturing NAICS (48 awards), with 144 awards classified under PSC Drugs And Biologicals. Beyond IXIARO, Valneva USA has delivered Chikungunya vaccine in small quantities and maintains an uncommitted BPA with FBI for a broad range of vaccines, but DLA procurement of Japanese encephalitis vaccine accounts for the vast majority of federal revenue. Place of performance is consistently Bethesda, Maryland, with references to a Potomac, Maryland facility in some award narratives. Valneva USA carries no federal subcontractors across its visible award portfolio and operates all work in-house. As a subsidiary of Valneva SE, a specialty vaccine manufacturer, Valneva USA functions as the U.S. distribution and contracting arm for a product portfolio focused on infectious disease vaccines with significant military readiness and public health implications.